Registration Programme Overview Exhibition Virtual Exhibition Satellite Programme Hotel Information VISA Letter Application

 

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Long-term results of ExPRESS glaucoma shunt surgery

Poster Details


First Author: R.Karadag TURKEY

Co Author(s): G. Kilic   F. Esen   V. Aykut   A. Demirok   H. Oguz        

Abstract Details

Purpose:

To present the results of long-term express implants in patients with primary open-angle and pseudoexfoliative glaucoma.

Setting:

Istanbul Medeniyet University School of Medicine.In this study; express implantation was performed by the same surgeon and sixteen eyes of 16 patients followed for at least 36 months were included.

Methods:

Efficacy was assessed according to the relevant intraocular pressure (IOP) values and postoperative non-drug duration and number of anti-glaucomatous agents.The mean age was 72.4±12.9 years. The mean follow-up period was 48.6±9.8 months. 10 of our patients (62.5%) are primary open-angle glaucoma (PAAG) and 6 (37.5%) are pseudoexfoliative glaucoma (PEX). 10 (62.5%) of our patients had undergone intraocular surgery before express surgery and 6 (37.5%) had no surgery.

Results:

It was determined that the patients did not use anti-glaucomatous medication for an average of 10 months after surgery. Postoperative intraocular pressure value (15.46±4.98 mmHg) was significantly lower than the preoperative IOP value (26.88±6.24 mmHg) (p=0.001). The number of anti-glaucomatous agents used in the postoperative period decreased significantly compared to the preoperative period (p=0.007). In the early postoperative period, 3 patients had wound site leakage and these resolved within a week without any surgical intervention. Six of our patients (mean 37.5%) were re-operated for revision due to blep fibrosis.

Conclusions:

Long-term results of express mini implant surgery without antimetabolite in primary open-angle and pseudoexfoliative glaucoma patients are effective.

Financial Disclosure:

None

Back to Poster listing